<code id='CEEC0CE2F0'></code><style id='CEEC0CE2F0'></style>
    • <acronym id='CEEC0CE2F0'></acronym>
      <center id='CEEC0CE2F0'><center id='CEEC0CE2F0'><tfoot id='CEEC0CE2F0'></tfoot></center><abbr id='CEEC0CE2F0'><dir id='CEEC0CE2F0'><tfoot id='CEEC0CE2F0'></tfoot><noframes id='CEEC0CE2F0'>

    • <optgroup id='CEEC0CE2F0'><strike id='CEEC0CE2F0'><sup id='CEEC0CE2F0'></sup></strike><code id='CEEC0CE2F0'></code></optgroup>
        1. <b id='CEEC0CE2F0'><label id='CEEC0CE2F0'><select id='CEEC0CE2F0'><dt id='CEEC0CE2F0'><span id='CEEC0CE2F0'></span></dt></select></label></b><u id='CEEC0CE2F0'></u>
          <i id='CEEC0CE2F0'><strike id='CEEC0CE2F0'><tt id='CEEC0CE2F0'><pre id='CEEC0CE2F0'></pre></tt></strike></i>

          fashion

          fashion

          author:comprehensive    Page View:3
          The ability of cancer cells to move and spread depends on actin-rich core structures such as the podosomes (yellow) shown here in melanoma cells. Cell nuclei (blue), actin (red), and an actin regulator (green) are also shown.
          Metastatic melanoma cells Julio C. Valencia,/NCI Center for Cancer Research

          Nearly four decades after its first conception, the first TIL therapy, an immunotherapy that harvests cancer-fighting immune cells from the patient’s own body, received accelerated approval from the Food and Drug Administration for advanced melanoma. The therapy, called Amtagvi or lifileucel from Iovance, is the first cell therapy approved for a solid tumor.

          “It’s so exciting and gratifying,” said Allison Betof Warner, a cell therapy researcher and physician at Stanford University who has worked on Amtagvi. “This is a game-changing moment for our field. We’ve seen huge success of cellular therapy for hematologic malignancies, and we’ve yet to capitalize on that for solid tumors. This is hopefully the first of many to come.”

          advertisement

          In a Phase 2 clinical trial, titled C-144-01, 153 patients who had already been on a median of three prior lines of therapy received lifileucel, and 31% of them responded to therapy. “These are in very late line patients. They’ve exhausted every standard care option,” Betof Warner said. “The most promising part of this therapy for me is that 42% of patients who responded were still responding for 18 months or longer. It’s truly incredible.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          American woman, child freed after being kidnapped in Haiti last month
          American woman, child freed after being kidnapped in Haiti last month

          0:26InthisundatedphotoprovidedbyElRoiHaiti,AlixDorsainvil,right,poseswithherhusband,SandroDorsainvil

          read more
          Virginia high school admissions case could be legal follow
          Virginia high school admissions case could be legal follow

          3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

          read more

          Medical mystery: When a cough is not just a cough

          MollyFergusonforSTATWhenCherylDaiglestartedcoughinginFebruary2013,shechalkedituptothesneezingandsnif